1. Home
  2. GRFS vs ESGR Comparison

GRFS vs ESGR Comparison

Compare GRFS & ESGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GRFS
  • ESGR
  • Stock Information
  • Founded
  • GRFS 1940
  • ESGR 2001
  • Country
  • GRFS Spain
  • ESGR Bermuda
  • Employees
  • GRFS N/A
  • ESGR N/A
  • Industry
  • GRFS Biotechnology: Pharmaceutical Preparations
  • ESGR Property-Casualty Insurers
  • Sector
  • GRFS Health Care
  • ESGR Finance
  • Exchange
  • GRFS Nasdaq
  • ESGR Nasdaq
  • Market Cap
  • GRFS 6.0B
  • ESGR 4.7B
  • IPO Year
  • GRFS 2006
  • ESGR N/A
  • Fundamental
  • Price
  • GRFS $8.59
  • ESGR $323.39
  • Analyst Decision
  • GRFS Sell
  • ESGR
  • Analyst Count
  • GRFS 2
  • ESGR 0
  • Target Price
  • GRFS $10.50
  • ESGR N/A
  • AVG Volume (30 Days)
  • GRFS 631.7K
  • ESGR 66.0K
  • Earning Date
  • GRFS 01-01-0001
  • ESGR 11-05-2024
  • Dividend Yield
  • GRFS N/A
  • ESGR N/A
  • EPS Growth
  • GRFS N/A
  • ESGR 307.45
  • EPS
  • GRFS 0.24
  • ESGR 58.61
  • Revenue
  • GRFS $7,297,379,191.00
  • ESGR $1,129,000,000.00
  • Revenue This Year
  • GRFS $12.18
  • ESGR N/A
  • Revenue Next Year
  • GRFS $3.75
  • ESGR N/A
  • P/E Ratio
  • GRFS $37.67
  • ESGR $5.53
  • Revenue Growth
  • GRFS 5.12
  • ESGR 393.01
  • 52 Week Low
  • GRFS $5.30
  • ESGR $229.57
  • 52 Week High
  • GRFS $12.15
  • ESGR $348.48
  • Technical
  • Relative Strength Index (RSI)
  • GRFS 46.69
  • ESGR 55.34
  • Support Level
  • GRFS $8.41
  • ESGR $321.45
  • Resistance Level
  • GRFS $8.76
  • ESGR $323.35
  • Average True Range (ATR)
  • GRFS 0.20
  • ESGR 1.94
  • MACD
  • GRFS -0.06
  • ESGR 0.35
  • Stochastic Oscillator
  • GRFS 26.47
  • ESGR 66.41

About GRFS Grifols S.A.

As a vertically integrated plasma derivative producer, Spain-based Grifols collects plasma and then manufactures and sells plasma-derived products globally. By acquiring Talecris in 2011, Grifols dramatically expanded its plasma-derived product portfolio, and following the firm's Biotest acquisition in April 2022, the biopharma business contributed 84% of sales in 2023. Grifols also has smaller segments including diagnostics (10% of sales) and biosupplies.

About ESGR Enstar Group Limited

Enstar Group Ltd is a (re)insurance group that offers capital release solutions through its network of group companies. It seeks to create value by managing (re)insurance companies and portfolios of (re)insurance and other liability businesses in run-off and striving to generate an attractive risk-adjusted return from its investment portfolio. Its operations are through four reportable segments: Run-off, Assumed Life, Investments, and Legacy Underwriting.

Share on Social Networks: